Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07430917 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of J147 in Acute Ischemic Stroke
A Phase 2 study, sponsored by Abrexa Pharmaceuticals.
- Not yet
- Registry status
- Phase 2
- Development phase
- 196
- Enrollment target
NCT07430917: Clinical Trial Phase 2 study, sponsored by Abrexa Pharmaceuticals.
NCT07430917 is a Phase 2 study that has not yet begun recruiting, run by Abrexa Pharmaceuticals. The registered enrollment target is 196 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07430917, a Phase 2 study, has not yet begun recruiting, sponsored by Abrexa Pharmaceuticals.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 196 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients. Researchers will compare the outcomes of those who receive J147 after therapy to clear the blood clot to those who don't receive J147. Participants will be asked to undergo a series of three to four magnetic resonance imaging (MRI) brain scans, and blood samples will be collected at several time points. Participants will also be evaluated to measure several aspects of brain function.
Primary Outcome
Continuous vital signs, 12-Lead ECG, and laboratory assessments will be summarized using descriptive statistics, which includes count, mean, median, standard deviation, min and max by treatment arm and visits. Incidence and severity of adverse events and serious adverse events will be summarized with count and percentages by treatment arm, overall and by System Organ Class and Preferred Term. Deaths will be listed.
Interventions
- OTHER Placebo
- DRUG J147 Emulsion for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2026-04-20 |
| Est. Completion | 2028-07-01 |
| Phase | Phase 2 |
What is known before NCT07430917 opens enrollment
NCT07430917 is an interventional study that assigns participants to a tested intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07430917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07430917 about?
NCT07430917 is a clinical study titled "Safety and Efficacy of J147 in Acute Ischemic Stroke". The goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients. Researchers will compare the outcomes of those who receive J147 after therapy to clea...
What is the current status of trial NCT07430917?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 196 participants. The study started on 2026-04-20. Estimated completion is 2028-07-01.
What interventions are being tested in trial NCT07430917?
The interventions under investigation include: Placebo (OTHER), J147 Emulsion for Injection (DRUG).
Who is sponsoring clinical trial NCT07430917?
This trial is sponsored by Abrexa Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07430917's enrollment target sits among peer trials
196 349th of 2000 higher than 1,651 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02822768 · 196 participants · NA
Packing Versus no Packing for Cutaneous Abscess
- NCT04250259 · 196 participants · Phase 2
SAMe Trial for Patients With Alcoholic Cirrhosis
- NCT05142592 · 196 participants · Phase 1
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
- NCT05317832 · 196 participants · Phase 2
Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI